肠道菌群调整对肝硬化病人血浆一氧化氮和内毒素水平影响

INFLUENCE OF ADJUSTED INTESTINAL MICROFLORA ON CHANGE OF PLASMA NITRIC OXIDE AND ENDOTOXIN LEVEL IN PATIENTS WITH CIRRHOSIS

本实验给肝硬化病人服用抑制肠源性内毒素血症的药物丽珠肠乐，结果表明：服用丽珠肠乐一个月后，血浆ＮＯ水平显著下降（Ｐ＜０．０１），白蛋白合成增多，门脉压力下降，肝功能显著改善，利于腹水消退，减少并发症的产生。其机制可能与内毒素水平降低有关。

In this experiment BIFIDOBIOGEN were per as for patients with cirrhosis,which inhibited enterogenous endotoxiema.After a month of BIFIDOBIOGEN treatment, the resuts showed the level of NO were significantly lower(P<001) and portal venous pressure fall,while albumin synthesis higher and liver function improved apparently,compared with control. It might be benefit ascited extinction and reduce complication production.